Partnership with UCSF researchers will support those living with multiple sclerosis
The not-for-profit Sutter Health network was awarded $1.2 million by the California Initiative to Advance Precision Medicine to support patients with multiple sclerosis—and help improve how we target and treat health matters across the entire state.
Sutter Health’s Research & Development team and colleagues from the University of California, San Francisco will jointly develop a software application called MS-SHARE. The neurology practice application will be used to improve the precision of care for multiple sclerosis (MS). Read More about Sutter Health receives $1.2 million grant by California Initiative to Advance Precision Medicine
Sutter Health, Validic Lead Pilot Demonstration to Capture, Share and Use Patient-Generated Health Data
Not-for-profit Sutter Health, recognized as an innovator in digital patient engagement, and Validic have begun a pilot demonstration to determine how patient-generated health data can best be delivered to care teams and researchers to improve the care and outcomes. The results of this work will inform federal government policy and help determine how the healthcare industry implements remotely-collected patient health data across the nation.
In health care today, many mobile applications, wearables and clinical in-home devices can collect patient data remotely. These devices help patients live with and manage chronic diseases. However, what is missing is a single, secure pipeline to deliver protected health data into the electronic health record or clinical dashboard so care teams can use the remote information effectively.
“We’re excited that Sutter Health is playing a leading role in a project that we expect to have a profound impact in how care teams use patient-generated health data. Creating a secure, effective pipeline for this data to the electronic health record establishes a connection between patients and clinicians like never before,” said Albert Chan, M.D., vice president and chief of digital patient experience.
Sutter Health advances cardiovascular service by offering first-of-its-kind fully dissolving heart stent in Bay Area and Sacramento
Recently approved by FDA, Absorb bioresorbable vascular scaffold opens clogged arteries to restore blood flow, then gradually dissolves in the body
Sutter Medical Center, Sacramento and Mills-Peninsula Health Services, both affiliates of Sutter Health, will be among the first in the country to offer patients with coronary artery disease a new treatment option, the Abbott Absorb stent, which literally disappears in the body over time.
Sailesh Shah, M.D., an interventional cardiologist at Sutter Medical Center and David Daniels, M.D., an interventional cardiologist at Mills-Peninsula will implant patients with the world’s first FDA-approved dissolving heart stent.
The Absorb bioresorbable vascular scaffold is a major advance in the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide despite decades of therapeutic advances.
While stents are traditionally made of metal, Abbott’s Absorb stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb disappears completely in about three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants.
“This is the first real game-changer in coronary stents since 2003, when drug-coated metal stents were developed, helping to reduce risk of renarrowing of the arteries,” Dr. Daniels explained. “With dissolving stents you have the best of both worlds: you have the benefit of using a less invasive procedure than open heart surgery, and then the stent disappears, leaving no metal behind to restrict motion of the blood vessels.” Read More about Sutter Health advances cardiovascular service by offering first-of-its-kind fully dissolving heart stent in Bay Area and Sacramento
Kevin Kim, M.D., a physician with Sutter Pacific Medical Foundation and director of clinical research for the Center for Melanoma Research and Treatment at Sutter Health’s California Pacific Medical Center (CPMC), will be honored with a Humanitarian Award from the Melanoma Research Foundation.
“Through his steadfast commitment to research and to his clinical practice, Dr. Kim embodies the dedication that this award represents,” said CPMC CEO Warren Browner, M.D., MPH. “Patients across California and beyond have benefited from his skills and accomplishments as a physician and scientist.”
Dr. Kim leads CPMC’s efforts to build a database and tumor bank of tissue samples from patients with melanoma. He and colleagues, including Mohammed Kashani-Sabet, M.D., will use these samples to create new diagnostic tests and personalized therapies for all stages of the disease. Read More about Sutter Health’s CPMC Physician Leader Honored with Humanitarian Award
Our not-for-profit Sutter Health network invites you to explore our online 2014 annual report. Through videos and other interactive features, see how our doctors, hospitals and medical teams partner to provide top-rated, personalized care in diverse communities across Northern California. This year our annual report focuses on our:
“At Sutter Health, we understand that in a rapidly changing world we must reimagine how we operate if we want to continue delivering the kind of quality care our patients expect and deserve,” said Sutter Health President and CEO Pat Fry. “In 2014, we implemented advanced technologies, pursued groundbreaking research, streamlined work processes and launched more convenient ways to access care.”
Boehringer Ingelheim, a family-owned biopharmaceutical company, and Sutter Health, a not-for-profit health system in Northern California, today announced the start of a five-year research and health care innovation collaboration, which will explore and test the value of digital health solutions, mobile technologies, and insights from advanced data analytics in the delivery of health care.
The organizations will work on initiatives that bring together Boehringer Ingelheim’s research and development expertise in novel medications to address unmet therapeutic needs with Sutter Health’s research and clinical experience from caring for a diverse population of more than 3 million patients in its network of hospitals and healthcare providers.
The first collaborative initiative will focus on chronic obstructive pulmonary disease (COPD). Chronic lower respiratory diseases, which include COPD, rank third in leading causes of death in the United States. Healthcare providers have told approximately 15 million Americans that they have COPD. Through this initial project, the team hopes to make it easier for doctors and patients to work together to personalize medical care to the patient’s unique needs and preferences.
“Ultimately, we all want to help patients reduce COPD symptoms and live healthier lives,” said Walter ‘Buzz’ Stewart, Ph.D., MPH, chief research officer for Sutter Health. “We believe that innovative technologies can help us develop a deeper understanding of patient needs, values, and care preferences—and create more time during office visits for doctors and patients to partner toward improved health outcomes.”
Specifically, the initial collaboration between the two companies aims to achieve the following:
- Develop a reliable, electronic (tablet or kiosk-based) data collection system to collect information directly from the patient, during every health encounter
- Make it easier for healthcare professionals and patients to communicate about treatment options by developing technological means for integrating clinical and patient reported data in an engaging visual display
- Empower shared decision making through the use of visual displays and other technologies that help connect patients and healthcare professionals and create more personal care